Finance

Lists
Why is ABVX down 4.53%?
Dive Deeper
ABVX:EPA
Abivax SA
€72.65
-4.53%
(-3.45) 1D
ኖቬም 20, 3:08:41 ከሰዓት ጂ ኤም ቲ+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ABVX...
Open
€74.50
High
€74.50
Low
€72.20
Mkt. cap
6.36 ቢ
Avg. vol.
112.96 ሺ
Volume
38.66 ሺ
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55 ሚ
No. of employees
98
Open
€74.50
High
€74.50
Low
€72.20
Mkt. cap
6.36 ቢ
Avg. vol.
112.96 ሺ
Volume
38.66 ሺ
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55 ሚ
No. of employees
98
News stories
From web sources and news partners
Idéal Investisseur
Idéal Investisseur
·
ከ3 ሰዓቶች በፊት
Abivax shares fall below their €75.50 floor and drop 11% in one week
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated. The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded4 ዲሴም 2013
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteabivax.com
Last report
21 ሴፕቴ 2026
Fiscal period
Q2 2026
- / -€0.61
Revenue / Est. (EUR)
976.00 ሺ / 814.89 ሺ
+19.77%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
ሴፕቴ 2025
ዲሴም 2025
ማርች 2026
ጁን 2026
Revenue
639.00 ሺ
1.91 ሚ
1.34 ሚ
976.00 ሺ
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
55.42 ሚ
44.40 ሚ
49.54 ሚ
58.34 ሚ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.34 ሚ
27.69 ሚ
8.03 ሚ
26.98 ሚ
Operating expense
81.35 ሚ
73.56 ሚ
57.57 ሚ
85.09 ሚ
Total operating expenses
81.35 ሚ
73.56 ሚ
57.57 ሚ
85.09 ሚ
Operating income
-80.71 ሚ
-71.65 ሚ
-56.23 ሚ
-84.11 ሚ
Other non operating income
-74.20 ሚ
-4.96 ሚ
119.00 ሺ
4.72 ሚ
EBT including unusual items
-153.36 ሚ
-76.11 ሚ
-48.24 ሚ
-123.51 ሚ
EBT excluding unusual items
-153.36 ሚ
-80.84 ሚ
-51.51 ሚ
-80.30 ሚ
Income tax expense
-
5.85 ሚ
228.00 ሺ
-6.08 ሚ
Effective tax rate
-
-7.68%
-0.47%
4.92%
Other operating expenses
-1.40 ሚ
1.47 ሚ
-
-225.00 ሺ
Net income
-153.36 ሚ
-81.96 ሚ
-48.47 ሚ
-117.43 ሚ
Net profit margin
-23,999.69%
-4,282.13%
-3,606.25%
-12,032.07%
Earnings per share
-
-
-
-
Interest and investment income
3.36 ሚ
1.19 ሚ
644.00 ሺ
-
Interest expense
-4.21 ሚ
-15.27 ሚ
-2.54 ሚ
-730.00 ሺ
Net interest expenses
-852.00 ሺ
-14.08 ሚ
-1.90 ሚ
-730.00 ሺ
Depreciation and amortization charges
-
-
-
-
EBITDA
-80.63 ሚ
-70.76 ሚ
-56.14 ሚ
-84.02 ሚ
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google መተግበሪያዎች